STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment

Welcome to STAT’s live blog of a meeting, convened by the Food and Drug Administration, to review Replimune’s experimental treatment for melanoma. The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee is meeting Thursday to evaluate whether the biotech company has collected sufficient data to support the accelerated approval of RP1, an engineered viral immunotherapy for melanoma. The agency tends to follow the recommendations of its expert panels but is not bound by them. The vote wi...